Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Children's Hospital Foundation has sold its worldwide royalty interest in respect of sales of RotaTeq from and after October 1, 2007, to Royalty Pharma for $182 million in cash.
Subscribe to our email newsletter
RotaTeq is a live, oral pentavalent vaccine indicated for the prevention of rotavirus gastroenteritis.
Pablo Legorreta, CEO of Royalty Pharma, said: “With the addition of this royalty on RotaTeq, we further our strategy of building a highly diversified portfolio of royalty interests on leading biopharmaceutical products. We are pleased to add the first vaccine to complement our royalties on products that treat a wide range of diseases, including cancer, rheumatoid arthritis and other autoimmune disorders, AIDS/HIV and neuropathic pain.”